AstraZeneca Vaccine Clinical Trial Provisional Results Average 70% Efficacy November 23, 19:56
British pharmaceutical giant AstraZeneca tentatively analyzed the new coronavirus vaccine under development in clinical trials with varying doses, with as high as 90% and an average of 70% efficacy. We announced the results.
In the future, as the data accumulates, the data on effectiveness will become more reliable.
The vaccine that AstraZeneca is developing with the University of Oxford in the United Kingdom is undergoing final clinical trials in the United Kingdom and other countries.
In this regard, AstraZeneca released preliminary results on the 23rd, analyzing data from clinical trials conducted by an independent external committee in the United Kingdom and Brazil.
According to the report, more than 23,000 people participated in clinical trials conducted in the United Kingdom and Brazil, and 131 people were confirmed to be infected with the new coronavirus.
In clinical trials, different doses of vaccine were analyzed in multiple groups, and the effectiveness of the vaccine was 90% for high vaccines, 62% for low vaccine doses, and 70% on average.
In addition, none of the people who became infected with the new coronavirus after receiving the vaccination needed to be hospitalized or became seriously ill.
AstraZeneca says that as data accumulates in the future, data on effectiveness will become more reliable.
It also means that there were no serious health effects associated with the vaccine.
AstraZeneca says it is preparing to provide data to regulators around the world that have frameworks for early approval.
Regarding the outlook for vaccine supply, AstraZeneca says it will be able to produce 3 billion doses next year, and the Japanese government has basically agreed to receive supply for 60 million people.